Validation of Vaginal Swab-derived EVs for Detection of Ovarian Cancer

View at publisher Summarise with VIRAT
Authors: Charlotte Robb
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Ovarian cancer (OC) remains one of the most lethal gynaecological malignancies, largely due to the absence of effective screening tools and biomarkers for early detection. The gold standard test of OC detection in NZ, i.e. circulating cancer antigen 125 (CA125) levels, is relatively non-specific and ineffective at detecting early disease. Small extracellular vesicles (EVs; 30–150 nm in size) and their encapsulated molecular cargo such as microRNAs (miRNAs) within the circulatory system have emerged as a new era of disease biomarker discovery. However, meaningful downstream applications rely upon the ability to isolate EVs with high purity and sufficient yield. Moreover, the ability to access biospecimens near the anatomical region of disease may increase their specificity and sensitivity. This study investigated the feasibility of isolating EVs from vaginal swabs of patients with OC, and evaluating their contents for novel EV-derived miRNA biomarkers of OC for their diagnostic potential. The first objective of this study trialled three isolation strategies (differential ultracentrifugation (dUC), size-exclusion chromatography (SEC), and dUC + SEC) for extracting EV populations from human serum. The EV isolates collected from the serum of three patients were processed as two technical replicates and characterised for size and concentration by tuneable resistive pulse sensing (TRPS), morphology by cryo-transmission electron microscopy (cryo-TEM), protein markers of EVs (CD63) and contaminants (GM130) by dot blotting, and miRNAs cargo markers of EVs (miR-16-5p and miR-21-5p) by reverse transcription quantitative PCR (RT-qPCR). Both individual methods (dUC-alone and SEC-alone) successfully isolated EVs of expected size (30 – 150 nm) and morphology, and containing known protein biomarkers and miRNA cargo. Importantly, SEC alone repeatedly produced the most uniform populations of EVs which ensured sufficient yield and purity to trial EV isolations from vaginal swab specimens. The combined dUC + SEC method compromised the structural integrity of EVs, leading to EV loss during the later steps of the procedure. The second objective of this study used the SEC method to prepare EV populations from vaginal swabs, to compare with matched serum, from patients with benign pathologies (n = 3) and high-grade serous OC (n = 6) (HGSOC). The EVs isolated from vaginal swabs were of expected size (30 – 150 nm) and morphology, and contained miRNA biomarkers of EVs. From within the EV isolates and the remaining (EV-depleted) fractions, recently discovered EV-derived miRNA biomarker candidates of early OC were quantified, and compared to CA125 levels, of serum and vaginal specimens. There were no significant differences in CA125 levels between sample types or pathologies. However, the early OC biomarker candidates, namely miR-200a-3p, miR-200b-3p, miR-200c-3p, miR-375-3p and miR-429, was significantly higher in vaginal swab-derived EVs, compared to their corresponding matched serum counterparts. This study is among the first to demonstrate the feasibility of isolating EVs from vaginal swabs specifically for OC diagnostic purposes and highlights their potential as a minimally invasive biospecimen for future early screening strategies.

Fields of Study & Subjects

Extracellular vesicles in disease Ovarian cancer diagnosis and treatment MicroRNA in disease regulation

Publication details

Journal / source
Open Access Victoria University of Wellington | Te Herenga Waka (Figshare)
Publication date
26 March 2026
Language
EN
Document type
Thesis